Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Tolerability of NGM395 in Adult Obese Patients and Patients With NAFLD
NCT04187339Phase 1Completed
- Sponsor
- NGM Biopharmaceuticals
- Start
- Feb 2020
- Primary completion
- Oct 2020
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of NGM395 in obesity and non-alcoholic fatty liver disease (NAFLD) (7 arms), sponsored by NGM Biopharmaceuticals. Primary endpoint: Incidence and Severity of Treatment-Emergent Adverse Events (TEAEs) at 140 Days. Started Feb 2020; status: completed.
02
Drugs
NGM395
03
Conditions
obesitynon-alcoholic fatty liver disease (NAFLD)
Beyond the preview
Go deeper on NCT04187339.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04187339.